Nature's Sunshine Products (NASDAQ:NATR) CAO Sells 5,000 Shares

Key Points

• CAO Jonathan David Lanoy of Nature's Sunshine Products sold 5,000 shares at an average price of $16.51, resulting in a transaction worth $82,550 and a 9.08% decrease in his ownership.
• The company's last quarterly earnings showed an EPS of $0.35, surpassing estimates of $0.16, with revenues of $114.75 million exceeding expectations.
• Analysts have positive outlooks for Nature's Sunshine Products, with a buy rating and price targets set between $19.00 and $22.00 based on recent reports.

Nature's Sunshine Products, Inc. (NASDAQ:NATR - Get Free Report) CAO Jonathan David Lanoy sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $16.51, for a total transaction of $82,550.00. Following the completion of the sale, the chief accounting officer owned 50,051 shares in the company, valued at $826,342.01. This represents a 9.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Nature's Sunshine Products Trading Down 1.9%

Shares of NATR traded down $0.32 during mid-day trading on Wednesday, reaching $16.49. 89,329 shares of the stock traded hands, compared to its average volume of 96,188. The company has a market cap of $290.88 million, a price-to-earnings ratio of 22.28 and a beta of 1.14. Nature's Sunshine Products, Inc. has a 1 year low of $11.01 and a 1 year high of $18.06. The firm has a fifty day moving average price of $15.27 and a 200 day moving average price of $14.09.

Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.35 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.19. Nature's Sunshine Products had a return on equity of 10.19% and a net margin of 3.06%.The business had revenue of $114.75 million for the quarter, compared to analyst estimates of $113.10 million. Nature's Sunshine Products has set its FY 2025 guidance at EPS.

Analysts Set New Price Targets

Several research analysts recently issued reports on NATR shares. Canaccord Genuity Group upped their target price on shares of Nature's Sunshine Products from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. DA Davidson reiterated a "buy" rating and set a $19.00 price objective on shares of Nature's Sunshine Products in a research report on Tuesday, June 3rd. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $19.67.

Hedge Funds Weigh In On Nature's Sunshine Products

A number of large investors have recently bought and sold shares of the stock. MTM Investment Management LLC bought a new stake in Nature's Sunshine Products in the second quarter valued at approximately $30,000. GAMMA Investing LLC increased its stake in shares of Nature's Sunshine Products by 2,090.2% in the first quarter. GAMMA Investing LLC now owns 2,234 shares of the company's stock worth $28,000 after buying an additional 2,132 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Nature's Sunshine Products in the second quarter worth $37,000. Russell Investments Group Ltd. bought a new stake in Nature's Sunshine Products during the 4th quarter valued at $41,000. Finally, Deutsche Bank AG purchased a new stake in Nature's Sunshine Products during the 4th quarter valued at $103,000. 79.40% of the stock is owned by hedge funds and other institutional investors.

Nature's Sunshine Products Company Profile

Nature's Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.